Blog

Economic Evaluation and Market Access for Medical Devices in the U.S.: Implications of a U.S. Health Technology Assessment Agency

Economic Evaluation and Market Access for Medical Devices in the U.S.: Implications of a U.S. Health Technology Assessment Agency 860 484 Avalon Health Economics LLC

The Biden Administration has indicated an intent to explore the creation of a government-operated health technology assessment (HTA) agency to engage in some form of review of biopharmaceuticals and other medical technologies.

read more

One Year into the Pandemic: Where are we Now?

One Year into the Pandemic: Where are we Now? 860 484 Avalon Health Economics LLC

In this blog entry, we briefly review where we are at now, one year after all of this started.

read more

Telehealth and Telemedicine in the Post-Pandemic Era

Telehealth and Telemedicine in the Post-Pandemic Era 860 484 Avalon Health Economics LLC

In many ways the arrival of the COVID-19 pandemic globally was met with sub-optimal levels of preparedness on the part of health care providers and provider systems, such as integrated delivery networks (IDNs).

read more

Moving Beyond ‘Lives-Saved’ From COVID-19

Moving Beyond ‘Lives-Saved’ From COVID-19 860 484 Avalon Health Economics LLC

This blog covers the presentation given as part of the ISPOR pre-conference plenary session on HEOR in the era of COVID-19 which was held on 14 May 2020.

read more

Economic Cycles and Product Development in Life Sciences

Economic Cycles and Product Development in Life Sciences 860 484 Avalon Health Economics LLC

The humanistic and economic consequences of the 2020 COVID-19 pandemic will not be completely understood for years. The humanistic toll has been well documented; as of early May 2020, the global death toll attributable to COVID-19 is more than 280,000, with more than 4 million confirmed cases.[1] Both numbers are believed to be substantial undercounts…

read more

Electronic Medical Records: Potential Issues in Litigation and Biomedical Research

Electronic Medical Records: Potential Issues in Litigation and Biomedical Research 860 484 Avalon Health Economics LLC

In this blog entry we explore some of the potentially important issues surrounding the role of EMRs in litigation, where the discovery of medical documents and records increasing involves digitally stored data.[1-4]

read more

Applications of HEOR Analytics: Covariate-Adjusted Analysis of Phase 3 Clinical Trial Data of Lenvatinib versus Sorafenib in Hepatocellular Carcinoma

Applications of HEOR Analytics: Covariate-Adjusted Analysis of Phase 3 Clinical Trial Data of Lenvatinib versus Sorafenib in Hepatocellular Carcinoma 860 484 Avalon Health Economics LLC

In this blog entry we report on a good example of HEOR analytics: our recent study of covariate-adjusted analysis of trial data of lenvatinib versus sorafenib in hepatocellular carcinoma.

read more

COVID-19: Update on Epidemiology & Costs

COVID-19: Update on Epidemiology & Costs 860 484 Avalon Health Economics LLC

We define epidemiology broadly, including an up-to-date review of the key published medical literature on COVID-19. Following that, our discussion of costs focuses in part on the direct medical costs (which probably for good reasons has been relatively under-reported) and in part on the broader costs to the economy.

read more

The Coronavirus: How Bad is it, Really?

The Coronavirus: How Bad is it, Really? 860 484 Avalon Health Economics LLC

Within a few months we’ve gone from worrying about holiday shopping to worrying about global pandemics and watching the world shut down around us. It started with news from China on the rapid spread of an insidious virus initially called a coronavirus.[1] Once the virus was better understood it became known as COVID-19. The disease…

read more

What is the Reasonable Value of Future Medical Care?

What is the Reasonable Value of Future Medical Care? 860 484 Avalon Health Economics LLC

A common challenge in economics and business is determining the fair-market value of products and services that have not yet “entered” the market. If consumers have not yet signaled a “willingness to pay” for the product or service, it is difficult to predict the fair market value. However, for products and services that fairly well defined,…

read more
Loading...